Xavier C. Badoux

2.3k total citations
60 papers, 1.4k citations indexed

About

Xavier C. Badoux is a scholar working on Genetics, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Xavier C. Badoux has authored 60 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Genetics, 36 papers in Pathology and Forensic Medicine and 16 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Xavier C. Badoux's work include Chronic Lymphocytic Leukemia Research (51 papers), Lymphoma Diagnosis and Treatment (35 papers) and Acute Lymphoblastic Leukemia research (14 papers). Xavier C. Badoux is often cited by papers focused on Chronic Lymphocytic Leukemia Research (51 papers), Lymphoma Diagnosis and Treatment (35 papers) and Acute Lymphoblastic Leukemia research (14 papers). Xavier C. Badoux collaborates with scholars based in United States, Australia and Italy. Xavier C. Badoux's co-authors include Michael J. Keating, Alessandra Ferrajoli, William G. Wierda, Stefan Faderl, Susan O’Brien, Jan A. Burger, Sijin Wen, Hagop M. Kantarjian, Susan Lerner and James M. Reuben and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Xavier C. Badoux

57 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xavier C. Badoux United States	21	1.1k	960	456	387	250	60	1.4k
Kerry A. Rogers United States	20	1.1k 1.0×	886 0.9×	410 0.9×	420 1.1×	257 1.0×	124	1.4k
Ben Kennedy United Kingdom	15	1.2k 1.1×	1.1k 1.1×	778 1.7×	268 0.7×	209 0.8×	26	1.5k
Pierre Feugier France	18	782 0.7×	715 0.7×	413 0.9×	217 0.6×	225 0.9×	68	1.1k
Alice Lynn United States	5	932 0.8×	674 0.7×	390 0.9×	281 0.7×	115 0.5×	8	990
Christian H. Geisler Denmark	19	779 0.7×	723 0.8×	449 1.0×	142 0.4×	278 1.1×	50	1.1k
Myriam Mendila Germany	9	778 0.7×	752 0.8×	390 0.9×	163 0.4×	148 0.6×	16	947
K Owusu-Ankomah United Kingdom	14	1.3k 1.1×	1.1k 1.2×	761 1.7×	194 0.5×	331 1.3×	17	1.6k
Ana Muntañola Spain	11	706 0.6×	672 0.7×	255 0.6×	211 0.5×	201 0.8×	30	956
Celeste Bello United States	13	640 0.6×	808 0.8×	247 0.5×	250 0.6×	544 2.2×	63	1.3k
Paul Moreton United Kingdom	12	712 0.6×	649 0.7×	425 0.9×	160 0.4×	104 0.4×	21	872

Countries citing papers authored by Xavier C. Badoux

Since Specialization

Citations

This map shows the geographic impact of Xavier C. Badoux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier C. Badoux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier C. Badoux more than expected).

Fields of papers citing papers by Xavier C. Badoux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier C. Badoux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier C. Badoux. The network helps show where Xavier C. Badoux may publish in the future.

Co-authorship network of co-authors of Xavier C. Badoux

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier C. Badoux. A scholar is included among the top collaborators of Xavier C. Badoux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier C. Badoux. Xavier C. Badoux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wierda, William G., Ryan Jacobs, Paul M. Barr, et al.. (2024). CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study. Clinical Lymphoma Myeloma & Leukemia. 24. S342–S342.

Wierda, William G., Ryan Jacobs, Paul M. Barr, et al.. (2024). Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study. Clinical Lymphoma Myeloma & Leukemia. 24. S179–S179.

Jain, Nitin, Lisa J. Croner, John N. Allan, et al.. (2023). Absence of BTK , BCL2 , and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clinical Cancer Research. 30(3). 498–505. 20 indexed citations

Trotman, Judith, Daniel Carradice, Maher K. Gandhi, et al.. (2023). Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study. HemaSphere. 7(3). e836–e836. 2 indexed citations

Tang, Catherine, Verity Chadwick, Kylie D. Mason, et al.. (2022). Capturing the lived experiences of women with lymphoma in pregnancy: a qualitative study. Leukemia & lymphoma. 64(2). 319–328. 6 indexed citations

Campbell, Belinda A., Kylie D. Mason, Matthew Greenwood, et al.. (2021). Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance. Blood. 138(Supplement 1). 882–882. 3 indexed citations

Tang, Catherine, Verity Chadwick, Kylie D. Mason, et al.. (2021). Capturing the Lived Experiences of Women with Lymphoma in Pregnancy: An Australasian Lymphoma Alliance Study. Blood. 138(Supplement 1). 4099–4099. 1 indexed citations

Tam, Constantine S., Tanya Siddiqi, John N. Allan, et al.. (2019). Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood. 134(Supplement_1). 35–35. 31 indexed citations

Tam, Constantine S., Hang Quach, Andrew J. Nicol, et al.. (2017). BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma. Blood. 130. 1745–1745. 1 indexed citations

10.

Davies, Andrew, Claude Berge, Anjum Dadabhoy, et al.. (2017). Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Advances in Therapy. 34(10). 2210–2231. 41 indexed citations

11.

Jones, Jeffrey A., Tadeusz Robak, Jennifer R. Brown, et al.. (2017). Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. The Lancet Haematology. 4(3). e114–e126. 154 indexed citations

12.

Assouline, Sarit, Valéria Buccheri, Alain Delmer, et al.. (2016). Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. The Lancet Haematology. 3(3). e128–e138. 35 indexed citations

13.

Jones, Jeffrey A., Tadeusz Robak, Małgorzata Wach, et al.. (2016). Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 34(15_suppl). 7515–7515. 13 indexed citations

14.

Tsimberidou, Apostolia M., William G. Wierda, Sijin Wen, et al.. (2013). Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome. Clinical Lymphoma Myeloma & Leukemia. 13(5). 568–574. 72 indexed citations

15.

Badoux, Xavier C., Michael J. Keating, Sijin Wen, et al.. (2012). Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 31(5). 584–591. 113 indexed citations

16.

Badoux, Xavier C., Carlos E. Bueso‐Ramos, David Harris, et al.. (2011). Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Human Pathology. 42(12). 1989–2000. 22 indexed citations

17.

Lee, Bang‐Ning, Hui Gao, Evan N. Cohen, et al.. (2011). Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 117(17). 3999–4008. 62 indexed citations

18.

Badoux, Xavier C., William G. Wierda, Susan O’Brien, et al.. (2010). A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia.. Journal of Clinical Oncology. 28(15_suppl). 6508–6508. 3 indexed citations

19.

Badoux, Xavier C., Michael J. Keating, & William G. Wierda. (2010). What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?. Current Hematologic Malignancy Reports. 6(1). 36–46. 17 indexed citations

20.

Badoux, Xavier C., Alessandra Ferrajoli, William G. Wierda, et al.. (2010). Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia.. Blood. 116(21). 4488–4488. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact